logo
St. Paul businesses call sinkhole timing a small blessing

St. Paul businesses call sinkhole timing a small blessing

Yahoo13-05-2025

The Minnesota Wild were eliminated from the Stanley Cup Play-offs on May 1, and a giant sinkhole opened up on West Seventh Street — a block away from the Xcel Energy Center — exactly one week later.
Coincidence?
Yes. Still, some businessowners are calling the timing a small blessing. No one wants a gaping hole running some 35 feet into the ground to open in front of their business. But if it had to happen, better that it take place in the post-season lull after professional hockey has let out and before the height of the summer concert season.
At the Downtowner Woodfire Grill, there's been 'no impact on our business,' said general manager Patrick Johnson, shortly after Tuesday's lunch rush. 'It's been busy.'
That sentiment was shared by a driver for Domino's pizza, a server at Tom Reid's Hockey City Pub and other frontline staff at West Seventh Street businesses. Private contractors under the supervision of St. Paul Public Works will spend up to two months repairing the man-sized sink hole that opened on the evening of May 8, forcing ongoing partial road closures between Chestnut and Walnut streets.
Officials with the Xcel Energy Center said their day-to-day operations and events are not impacted by the sinkhole. They reminded fans attending Wednesday's Minnesota Frost game that they need to plan ahead due to road closures connected with the sinkhole.
General traffic is being detoured between Kellogg Boulevard and Grand Avenue, though West Seventh in that stretch remains open for local business access, with one lane open in each direction. Sidewalks are unaffected.
'We don't want through-traffic there,' said Lisa Hiebert, spokesperson for St. Paul Public Works, on Tuesday. 'This is why we're saying local business access only.'
Otherwise, there have been no direct water or sewer impacts reported by businesses, according to the city.
City crews are examining whether water may have loosened and weakened the earth in the affected area.
'It's a good argument for why we need to reconstruct roads,' Hiebert said. 'What we can say is a lot of time, sinkholes are caused by voids caused by water, but it's still a little early to say what it was and what it wasn't. Sources of water can come from many places.'
Filling the hole will be no simple patch job. Contractors will have to dig more than 30 feet through sandstone and limestone, assess damages and then rebuild the sanitary sewer tunnel.
The work, which began Monday, will involve installing new utility connections for surrounding businesses, building out a new shaft to the surface and then replacing the road surface, without damaging a 20-inch water main. To ensure worker safety, crews will install temporary supports for the depth of the project.
'Nobody ever wants things like this to happen, but this is a good example of how quickly the city and the agencies came together to limit impacts to businesses in the surrounding area,' Hiebert said. 'The businesses, everybody was really great to work with.'
Giant sinkhole on West Seventh Street will require digging down 30 feet
Public media outlets MPR and TPT brace for federal funding cuts
Thirty-five-foot sinkhole shuts down part of West 7th Street
St. Paul, MN Wild trim Xcel Center's state request from $400M to $50M
Minnesota loosens distance exemption on state employee return to office order

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Wild searching for new AHL coach after Brett McLean hired as Canucks assistant
Wild searching for new AHL coach after Brett McLean hired as Canucks assistant

New York Times

time2 days ago

  • New York Times

Wild searching for new AHL coach after Brett McLean hired as Canucks assistant

Less than a month after Minnesota Wild president of hockey operations and general manager Bill Guerin said he was not firing Brett McLean following two tough seasons as AHL Iowa's head coach, the organization will now conduct a coaching search to replace McLean, who was hired to Adam Foote's Vancouver Canucks staff on Thursday. Advertisement Iowa had identical 27-37-8 records the past two seasons, finishing 30th in the AHL in 2024-25 and 29th in 2023-24. This past season, Iowa ranked 32nd on the power play and penalty kill, 28th in goals scored and 31st in goals against. McLean spent three seasons as an assistant coach with Minnesota before being persuaded by Guerin to take his first head coaching job two years ago. Reached Thursday afternoon, Guerin said he will be involved in the search, which will be led Iowa Wild GM Matt Hendricks. The organization has a short list of candidates it would like to talk to. One possibility may be Iowa assistant coach Ben Simon, who spent five seasons as AHL Grand Rapids' head coach. 'We don't have a long list but some great coaches we're interested in,' Guerin said. During McLean's tenure on Minnesota's bench, the Wild made the playoffs in three consecutive seasons and went 134-63-23 (.661) — the sixth-best points percentage in the NHL during the span. Prior to Minnesota, he was an assistant coach with Iowa for three years. A native of Comox, B.C., McLean owns BNA Brewing in Kelowna. McLean, 46, was a high-energy, good-skating forward who played professionally for 18 seasons, compiling 1,111 games across the NHL, AHL, IHL, ECHL, SEL, Swiss-A and the Austrian League. He scored 162 points in 385 career games with the Blackhawks, Avalanche and Panthers but just missed playing with Foote with the Avs.

Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia

Yahoo

time2 days ago

  • Yahoo

Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia

Exclusive-Licensing Partner Santen Will Commercialize SYD-101 Under the Brand Name Ryjunea® in the European Union DEL MAR, Calif., June 05, 2025--(BUSINESS WIRE)--Sydnexis, Inc., ( a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company's proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia. As the first and only approved pharmaceutical treatment option to treat myopia progression in EU countries, this approval marks a significant advancement in pediatric eye care. The approval is backed by data from the STAR study, Sydnexis' pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow the progression of pediatric myopia and the risk of associated co-morbidities in children 3 to 14 years old at treatment initiation. "This marks a significant milestone for Sydnexis and, most importantly, for pediatric patients with progressive myopia, their families, and physicians as the first and only approved pharmaceutical treatment option in Europe," said Perry Sternberg, Chief Executive Officer of Sydnexis. "This approval is an endorsement of the potential benefit SYD-101 can provide to millions of patients globally and reinforces the critical importance of early intervention." The marketing approval from the EC follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP). Santen, a Japan-based company specialized in eye health, offering innovative products and services in over 60 countries worldwide, licensed the rights from Sydnexis to commercialize SYD-101 in the regions of Europe, Middle East, and Africa (EMEA) and will launch SYD-101 under the brand name Ryjunea. "The EU approval of SYD-101 is a recognition of the compelling safety and efficacy data generated from our landmark STAR study," said Patrick Johnson, Ph.D., President of Sydnexis. "This validates the potential benefit that SYD-101 can provide to pediatric myopes in Europe and we are excited about our continued interactions with the Food and Drug Administration (FDA) leading up to our October 23 PDUFA date." Myopia is the most common eye disease in children, impacting approximately one-third of children and adolescents worldwide. By 2050, global prevalence is projected to increase and affect more than 740 million children and adolescents and 5 billion people in total. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious irreversible sight-threatening co-morbidities later in life. "As a Pediatric Ophthalmologist with a rapidly growing number of myopia patients around the world, the EU approval of SYD-101 is truly exciting and it provides an important new tool for physicians to combat this global epidemic," said Dr. Donny Suh, Gavin Herbert Eye Institute, University of California at Irvine. "The benefits of low-dose atropine have long been recognized in the eye care community, but we now finally have an approved and thoroughly vetted treatment option. This marks a new era in our ability to slow the progression of myopia and protect the vision of millions of children worldwide." About Sydnexis, Inc.: Founded in 2014, Sydnexis, Inc. ( is a privately held, pre-commercial stage biopharmaceutical company based in San Diego, California. Sydnexis recently completed its three-year primary endpoint in the pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the risk of associated co-morbidities. The Phase 3 clinical trial is now completing the fourth-year randomized withdrawal for exploratory endpoints and third year results will be announced upon completion of the fourth year of the study. The company is venture-backed by four major investors: Visionary Ventures, RA Capital, Longitude Capital, and Bluestem Capital. View source version on Contacts For media inquiries, please contact: media@

Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia
Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia

Business Wire

time2 days ago

  • Business Wire

Sydnexis Announces European Commission Approval of SYD-101, the First and Only Pharmaceutical Treatment for Slowing the Progression of Pediatric Myopia

DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., ( a pre-commercial stage biopharmaceutical company today announced that the European Commission (EC) has granted marketing authorization for SYD-101, the company's proprietary low-dose atropine formulation, for slowing the progression of pediatric myopia. As the first and only approved pharmaceutical treatment option to treat myopia progression in EU countries, this approval marks a significant advancement in pediatric eye care. The approval is backed by data from the STAR study, Sydnexis' pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow the progression of pediatric myopia and the risk of associated co-morbidities in children 3 to 14 years old at treatment initiation. 'This marks a significant milestone for Sydnexis and, most importantly, for pediatric patients with progressive myopia, their families, and physicians as the first and only approved pharmaceutical treatment option in Europe,' said Perry Sternberg, Chief Executive Officer of Sydnexis. 'This approval is an endorsement of the potential benefit SYD-101 can provide to millions of patients globally and reinforces the critical importance of early intervention.' The marketing approval from the EC follows the recent positive opinion from the Committee for Medicinal Products for Human Use (CHMP). Santen, a Japan-based company specialized in eye health, offering innovative products and services in over 60 countries worldwide, licensed the rights from Sydnexis to commercialize SYD-101 in the regions of Europe, Middle East, and Africa (EMEA) and will launch SYD-101 under the brand name Ryjunea. 'The EU approval of SYD-101 is a recognition of the compelling safety and efficacy data generated from our landmark STAR study,' said Patrick Johnson, Ph.D., President of Sydnexis. 'This validates the potential benefit that SYD-101 can provide to pediatric myopes in Europe and we are excited about our continued interactions with the Food and Drug Administration (FDA) leading up to our October 23 PDUFA date.' Myopia is the most common eye disease in children, impacting approximately one-third of children and adolescents worldwide. By 2050, global prevalence is projected to increase and affect more than 740 million children and adolescents and 5 billion people in total. Once considered a benign refractive condition, even at low levels, myopia is now associated with many serious irreversible sight-threatening co-morbidities later in life. 'As a Pediatric Ophthalmologist with a rapidly growing number of myopia patients around the world, the EU approval of SYD-101 is truly exciting and it provides an important new tool for physicians to combat this global epidemic,' said Dr. Donny Suh, Gavin Herbert Eye Institute, University of California at Irvine. 'The benefits of low-dose atropine have long been recognized in the eye care community, but we now finally have an approved and thoroughly vetted treatment option. This marks a new era in our ability to slow the progression of myopia and protect the vision of millions of children worldwide.' About Sydnexis, Inc.: Founded in 2014, Sydnexis, Inc. ( is a privately held, pre-commercial stage biopharmaceutical company based in San Diego, California. Sydnexis recently completed its three-year primary endpoint in the pivotal Phase 3 clinical trial evaluating its proprietary low-dose atropine formulation to slow progression of pediatric myopia and the risk of associated co-morbidities. The Phase 3 clinical trial is now completing the fourth-year randomized withdrawal for exploratory endpoints and third year results will be announced upon completion of the fourth year of the study. The company is venture-backed by four major investors: Visionary Ventures, RA Capital, Longitude Capital, and Bluestem Capital.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store